SCHEMBL1938313

SCHEMBL1938313

CCc1cnc(N2CCC(COc3c(F)cc(-c4ccc(CC#N)cc4)cc3F)CC2)nc1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 15/20 0.49
HRH3 Q9Y5N1 1/20 0.38
KDM1A O60341 1/20 0.36
FFAR4 Q5NUL3 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1936232 0.90 GPR119 (0.51) GPR119HRH3KDM1A
SCHEMBL1935878 0.90 GPR119 (0.45) GPR119FFAR4
SCHEMBL1937372 0.88 GPR119 (0.49) GPR119FFAR4
SCHEMBL1938226 0.87 GPR119 (0.53) GPR119FFAR4
SCHEMBL1937276 0.87 GPR119 (0.53) GPR119FFAR4
SCHEMBL1936561 0.87 GPR119 (0.51) GPR119HRH3FFAR4
SCHEMBL1937700 0.86 GPR119 (0.51) GPR119FFAR4
SCHEMBL1937615 0.85 GPR119 (0.50) GPR119FFAR4
SCHEMBL15196511 0.85 GPR119 (0.49) GPR119FFAR4
SCHEMBL1938864 0.84 GPR119 (0.49) GPR119HRH3FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP claimed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US claimed
JP-2011527701-A 2011-11-04 JP claimed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US claimed
EP-2331503-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-06-15 EP claimed
WO-2010006191-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-14 WO claimed
US-20160051688-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY UNIV INDIANA RES & TECH CORP (US) 2016-02-25 US disclosed
US-9145451-B2 Glucagon superfamily peptides exhbiting G protein coupled receptor activity INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-09-29 US disclosed
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP disclosed
US-20130116172-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY MARCADIA BIOTECH, INC. (US) 2013-05-09 US disclosed
EP-2568993-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY Indiana University Research and Technology Corporation (US) 2013-03-20 EP disclosed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US disclosed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US disclosed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US disclosed
WO-2011143208-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-11-17 WO disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
EP-2331503-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-06-15 EP disclosed
WO-2010006191-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116172-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY GCGR, GLP1R, GIPR GPR119 4/4885HRH3 1096/4885KDM1A 4166/4885
US-20160051688-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY GCGR, GLP1R, GIPR GPR119 4/4885HRH3 1357/4885KDM1A 4287/4885
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR4, GPR180 GPR119 1/4885HRH3 306/4885KDM1A 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.